在本次大会上,一项题为“Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia(2022年欧洲白血病网(ELN)急性髓系白血病(AML)风险分层的验证)”的研究入选壁报展示(P4310),为AML风险分层带来重要启示。...
在本次大会上,一项题为“Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia(2022年欧洲白血病网(ELN)急性髓系白血病(AML)风险分层的验证)”的研究入选壁报展示(P4310),为AML风险分层带来重要启示。本期特整理如下,供大家提前阅览。 研究简介 背景 AML在临床结局和疾病生物学...
[3]Aparicio Pérez C, Gonzalez Teomiro A C, Martinez Losada M C, et al. Real-Life Comparative Analysis of Prognostic Risk Classification According to ELN 2010, 2017 and 2022 in AML Patients[J]. Blood, 2022, 140(Supplement...
在本次大会上,一项题为“Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia(2022年欧洲白血病网(ELN)急性髓系白血病(AML)风险分层的验证)”的研究入选壁报展示(P4310),为AML风险分层带来重要启示。本期特整理如下,供大家提前阅览。 研究简介 背景 AML在临床结局和疾病生物学...
Due to the small number of prospective Minimal Residual Disease (MRD) driven studies, the MRD role in AML risk stratification is not clearly defined.The aim of this study was to evaluate the effect of MRD in a real-life setting. We retrospectively analyzed 124 patients with Favorable (FAV) ...
2022_ELN_Favorable_Code.Rmd 2022_ELN_Favorable_Data.RData KJArcher_hdcuremodels_06-13-2024.pdf README.md hdcuremodels_0.0.1.tar.gz 2022_ELN_Favorable_Code.Rmd R code for replicating results in Archer et al., "Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients...
We conducted a retrospective, single-center study to investigate the impact of hyperleukocytosis on the response and prognosis of favorable-risk AML according to ELN-2022 risk classification. Method: We retrospectively enrolled 217 favorable-risk AML patients, excluding acute promyelocytic leukemia (APL)...
et al. Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study. Leukemia 35, 1291–1300 (2021). https://doi.org/10.1038/s41375-020-01031-1 Download citation Received27 April 2020 Revised23 July 2020 Accepted14 August 2020 Published18 ...
European LeukemiaNet (ELN) 2017 updated prognostic system for acute myeloid leukemia (AML), which incorporates both cytogenetic and molecular risks, stratifying patients into 3 distinct genetic risk groups: favorable, intermediate and adverse. While most patients in favorable risk group can be cured wi...
ELN2017 risk group ELN2017-IR vs ELN2017-FR .0003 1.838 1.321 2.557 Transplant, covariate time-dependent Transplant vs no transplant .0185 0.674 0.485 0.936 Discussion In the current analysis, we showed that, when implemented in the prospective, risk-adapted, MRD-driven, AML1310 GIMEMA protocol...